CH 223191: Precision Aryl Hydrocarbon Receptor Antagonist for Environmental Toxicology and Intestinal Stem Cell Research

Introduction: Principle and Research Context

CH 223191 is a highly potent and selective aryl hydrocarbon receptor (AhR) antagonist validated for both in vitro and in vivo systems. As environmental toxicology research advances, the need for precise modulation of transcription factor-mediated pathways—particularly those implicated in dioxin toxicity and inflammation—has never been greater. The compound's ability to inhibit AhR-mediated transcriptional activation at IC₅₀ values around 30 nM in cellular assays positions it as a benchmark tool for dissecting the molecular underpinnings of toxicant response and stem cell fate decisions [source_type: product_spec][source_link: https://www.apexbt.com/ch-223191.html].

Recent findings, such as those from Li et al. (2026), have expanded the applied scope of CH 223191 far beyond classical toxicology, demonstrating its pivotal role in modulating the microbiota–tryptophan metabolism–AhR–intestinal stem cell (ISC) differentiation axis in the context of ulcerative colitis repair. This article maps out how to leverage CH 223191 from APExBIO for advanced workflows, troubleshooting, and experimental design across these domains.

Setting Up: Compound Handling and Assay Preparation

CH 223191 arrives as a high-purity solid (≥98% by HPLC/NMR) with a molecular weight of 333.39 (C₁₉H₁₉N₅O). Its solubility profile supports dissolution at ≥33.3 mg/mL in DMSO and ≥2.31 mg/mL in ethanol, but it is insoluble in water [source_type: product_spec][source_link: https://www.apexbt.com/ch-223191.html]. For optimal stability, store the compound at -20°C, and prepare aliquots to avoid repeated freeze-thaw cycles. Solutions should be prepared fresh and used promptly as long-term storage diminishes activity [source_type: product_spec][source_link: https://www.apexbt.com/ch-223191.html].

Protocol Parameters

• assay: Cell-based AhR reporter | value_with_unit: 30 nM CH 223191 | applicability: Inhibition of TCDD-induced reporter activity | rationale: Achieves near-complete blockade of AhR transcriptional activation in vitro | source_type: product_spec [source_link: https://www.apexbt.com/ch-223191.html]
• assay: In vivo TCDD toxicity mitigation | value_with_unit: 10 mg/kg CH 223191 (i.p., daily) | applicability: Reduces hepatic CYP1A1 expression and plasma AST/ALT elevations in mouse models | rationale: Validated suppression of AhR target gene induction and liver damage markers | source_type: product_spec [source_link: https://www.apexbt.com/ch-223191.html]
• assay: Microbiota–AhR–ISC differentiation axis | value_with_unit: 10–50 μM CH 223191 in colonic organoid cultures | applicability: Blocks AhR-mediated effects of microbial tryptophan metabolites on ISC differentiation | rationale: Dose range effective in ex vivo organoid and tissue explant systems | source_type: workflow_recommendation

Step-by-Step Workflow: Experimental Design Using CH 223191

Deploying CH 223191 in your workflow begins with careful solution preparation and pilot titrations. Here’s how to integrate the compound into environmental toxicology or stem cell differentiation assays:

1. Solution Preparation: Dissolve CH 223191 in DMSO to a 10 mM stock concentration. For cell assays, dilute into culture medium to final working concentrations (e.g., 30 nM–10 μM), keeping DMSO ≤0.1% to avoid solvent toxicity [source_type: workflow_recommendation].
2. Control Setup: Always include DMSO vehicle, untreated, and positive control groups (e.g., TCDD or indole-3-propionic acid as AhR agonists) for accurate interpretation of antagonism.
3. Timing and Dosage: For acute pathway inhibition, pre-incubate cells with CH 223191 for 30–60 minutes before agonist addition. For in vivo studies, administer daily intraperitoneal doses (e.g., 10 mg/kg) and assess endpoint readouts 24–72 hours post-treatment [source_type: product_spec][source_link: https://www.apexbt.com/ch-223191.html].
4. Assay Readouts: Quantify target gene expression (e.g., CYP1A1, IL-22), protein levels, or functional endpoints (e.g., disease activity indices, epithelial differentiation markers) via RT-qPCR, ELISA, immunofluorescence, or Western blot.
5. Workflow Integration: In complex systems (e.g., organoids, in vivo colitis models), coordinate CH 223191 treatment with microbial manipulations, metabolic profiling, and lineage tracing to dissect the microbiota–AhR–ISC axis [source_type: paper][source_link: https://doi.org/10.1186/s13020-025-01302-y].

Key Innovation from the Reference Study

The study by Li et al. (2026) demonstrated, for the first time, that blocking AhR signaling with an antagonist like CH 223191 abolishes the therapeutic effects of microbiota-derived tryptophan metabolites in models of ulcerative colitis. Specifically, the research showed that HQD (a traditional herbal decoction) repaired mucosal damage by elevating microbial indole derivatives, which activate AhR and promote ISC differentiation into mature epithelial cells. Critically, these effects were lost when CH 223191 was co-administered, confirming the centrality of the AhR axis in this regenerative mechanism [source_type: paper][source_link: https://doi.org/10.1186/s13020-025-01302-y].

Translation for Assay Design: For researchers probing gut repair, ISC fate, or microbiota–host crosstalk, including CH 223191 in co-treatment arms provides a powerful negative control to validate AhR-dependence. Use in organoid or animal studies at 10–50 μM (in vitro) or 10 mg/kg (in vivo) to dissect pathway specificity and mechanistic causality [source_type: workflow_recommendation].

Advanced Applications and Comparative Advantages

CH 223191’s nanomolar potency and selectivity offer several unique advantages:

• Dioxin Toxicity Mechanism Studies: As shown in multiple studies (see CH 223191: Potent AhR Antagonist for Dioxin Toxicity Mechanism Studies), CH 223191 enables precise inhibition of TCDD-induced gene expression, such as CYP1A1, without off-target effects, supporting its role as a gold-standard tool for environmental toxicology [source_type: product_spec][source_link: https://www.apexbt.com/ch-223191.html].
• Microbiota–AhR–ISC Axis Dissection: The reference study’s workflow extends the application of CH 223191 to regenerative medicine and intestinal biology, facilitating the mechanistic dissection of how gut-derived metabolites modulate epithelial repair—a crucial advance over prior broad-spectrum, less-specific AhR inhibitors.
• Complementary Insights: Recent reviews (see Unlocking the Microbiota–AhR Axis for Next-Level Toxicology) highlight how CH 223191’s utility bridges toxicology and stem cell research, providing a unique comparative advantage in cross-disciplinary studies.

By sourcing your CH 223191 from APExBIO, you ensure assay consistency, batch-to-batch reproducibility, and regulatory-grade purity, which is critical for both publication and translational research.

Troubleshooting & Optimization Tips

• Solubility Pitfalls: If precipitation occurs in aqueous media, confirm complete dissolution in DMSO or ethanol before dilution. Avoid exceeding 0.1% DMSO in final cell culture to minimize cytotoxic effects [source_type: product_spec][source_link: https://www.apexbt.com/ch-223191.html].
• Batch Variability: Always record lot numbers and verify purity by HPLC/NMR if running high-sensitivity endpoints. APExBIO provides lot-specific certificates for traceability.
• Assay Controls: Include AhR agonists and unrelated pathway inhibitors to distinguish specific from off-target effects. In complex systems (e.g., in vivo tissue repair), use parallel arms with antibiotics or microbiota modulation to confirm pathway specificity, as in the Li et al. study.
• Optimal Dosing: Validate the minimal effective dose for your biological system via pilot titrations, especially if translating from cell culture to animal models. AhR expression and ligand availability may differ by tissue or species [source_type: workflow_recommendation].
• Endpoint Timing: For regenerative assays, monitor both immediate and delayed markers (e.g., Lgr5 for ISC, MUC2/LYZ/ChgA for differentiated lineages) to capture transient versus sustained pathway modulation.

Interlinking Related Research: Complement, Contrast, and Extension

For researchers wishing to further contextualize their findings, several recent articles offer complementary and extended insights:

• CH 223191: Potent AhR Antagonist for Dioxin Toxicity Mechanism Studies (complement): Focuses on environmental toxicant response and hepatic endpoints, supporting the quantitative claims for CYP1A1 and transaminase modulation.
• Unlocking the Microbiota–AhR Axis for Next-Level Toxicology (extension): Explores emerging applications in the interplay between the microbiome, AhR signaling, and epithelial regeneration.
• CH 223191: Highly Selective AhR Antagonist in Toxicology (contrast): Details selectivity metrics and provides comparative analysis against other AhR inhibitors, useful for protocol refinement.

Future Outlook: Implications and Emerging Directions

As elucidated in both the reference and recent literature, the integration of CH 223191 into experimental workflows is reshaping our understanding of environmental toxicant response, gut–host signaling, and tissue regeneration. The ability to deploy a highly selective aryl hydrocarbon receptor antagonist at defined nanomolar concentrations enables rigorous mechanistic dissection of the AhR axis in settings ranging from hepatic toxicity to epithelial barrier repair.

Looking forward, this compound will underpin a new generation of studies that bridge environmental toxicology, stem cell biology, and host–microbiota interaction, as demonstrated by the paradigm-shifting findings of Li et al. (2026). By refining dosing strategies and integrating multi-omic endpoints, researchers can unlock new therapeutic avenues for conditions such as ulcerative colitis, toxin-induced liver injury, and beyond—all with the validated precision of CH 223191 from APExBIO.